Role of the Prostaglandin E Receptor Subtype EP1 in Colon Carcinogenesis

Kouji Watanabe, Toshikiko Kawamori, Seiichi Nakatsugi, Toshihisa Ohta, Shuichi Ohuchida, Hiroshi Yamamoto, Takayuki Maruyama, Kigen Kondo, Fumitaka Ushikubi, Shuh Narumiya, Takashi Sugimura, and Keiji Wakabayashi

Cancer Prevention Division, National Cancer Center Research Institute, Tokyo 104-0045, Japan [K. Wat., T. K., S. Nak., T. O., T. S., K. Wak.]; Minase Research Institute, Ono Pharmaceutical Co. Ltd., Osaka 618-8585, Japan [S. O., H. Y., T. M., K. K.]; and Department of Pharmacology, Faculty of Medicine, Kyoto University, Kyoto 606-8315, Japan [F. U., S. Nar.]

Abstract

Although the cyclooxygenase pathway of the arachidonic acid cascade has been suggested to play an important role in colon carcinogenesis, the molecular species of prostanoids and receptors involved have not been fully elucidated yet. We examined the development of aberrant crypt foci (ACFs), putative preneoplastic lesions of the colon, in two lines of knockout mice, each deficient in prostaglandin E receptors, EP1 and EP3, by treatment with the colon carcinogen, azoxymethane. Formation of ACFs was decreased only in the EP1-knockout mice to ~60% of the level in wild-type mice. Administration of 250, 500, or 1000 ppm of a novel selective EP1 antagonist, ONO-8711, in the diet to azoxymethane-treated C57BL/6J mice also resulted in a dose-dependent reduction of ACF formation. Moreover, when Min mice, having a nonsense mutation in the Apc gene, were treated with the colon carcinogen, azoxymethane, the number of intestinal polyps was significantly reduced to 57% of that in the basal diet group. These results strongly suggest that prostaglandin E1 contributes to colon carcinogenesis to some extent through its action at the EP1 receptor. Thus, EP1 antagonists may be good candidates as chemopreventive agents for colon cancer.

Introduction

Colon cancer is one of the most common malignancies in humans. Epidemiological studies have revealed a significant decrease in the death rates from colon cancer in individuals who have taken aspirin, a NSAID, for prolonged periods (1). Various NSAIDs also inhibit chemically induced colon carcinogenesis in rodents (2, 3), and the NSAID sulindac reduced the number and size of intestinal polyps in patients with familial adenomatous polyposis (4, 5). The common mechanism of action of NSAIDs is the inhibition of COX, which catalyzes the synthesis of prostanoids such as PGs and TXs.

Two isoforms of COX, referred to as COX-1 and COX-2, have been identified. COX-1 is expressed constitutively and participates in various physiological functions, whereas COX-2 is inducible and contributes to pathological processes such as inflammation and abnormal cell proliferation (6). The abundance of COX-2 is increased in colon carcinomas of humans and rodents (7, 8), and the number and size of intestinal polyps in the offspring of crosses between COX-2 gene knockout mice and Apc knockout mice are markedly decreased relative to those apparent in the parental animals (9). These observations suggest that COX-2 and, by inference, the prostanoids formed by the action of this isozyme play an important role in colon carcinogenesis. However, whether prostanoids actually contribute to this process and, if so, the identity of the specific prostanoid responsible remain unknown.

The prostanoids PGE2, PGF2, PGG2, PGI2, and TXA2 exert their biological actions through binding to specific receptors with seven transmembrane domains. These receptors include DP for PGD2, FP for PGF2, IP for PGH2, TP for TXA2, and the four subtypes EP1 to EP4 for the prostanoids or EP1- and EP3-knockout mice for the experiments because the numbers of EP2- and EP4-knockout mice available are very limited because of failure of fertilization or death in the neonatal period (15, 18). In the present study, we therefore examined the development of ACFs, putative preneoplastic lesions of the colon (19), in two lines of mice lacking EP1 or EP3 receptors for PGE2 (14). The results indicated a requirement for the EP3 receptor in ACF induction by the colon carcinogen, AOM. To confirm these results, a newly developed selective EP1 antagonist, ONO-8711, was tested for chemopreventive effects on development of AOM-induced ACF in mice and of intestinal polyps in Min mice containing a nonsense mutation of the Apc gene.

Materials and Methods

Animals. Male C57BL/6J mice were purchased from CLEA Japan (Tokyo, Japan) and male Min mice were purchased from The Jackson Laboratory (Bar Harbor, ME) at 5 weeks of age. The mouse genes encoding EP1 or EP3 receptors were disrupted by gene knockout methods using homologous recombination, as reported previously (14). The generated chimeric mice were back-crossed with C57BL/6 mice, and the resulting wild-type and homozygous mutant male mice of these F2 progeny were used at 7 (EP1) and 12 (EP3) weeks of age. Genotypes of these knockout mice were confirmed by PCR according to the method described previously (15). The animals were housed in plastic cages at 24 ± 2°C and 55% humidity with a 12-h light-dark cycle. Water and basal diet (AIN-76A; Bio-Serv, Frenchtown, NJ) or experimental diets prepared once every 2 weeks were given ad libitum. Body weights were measured weekly.

AOM-induced ACF Development in Prostanoid Receptor-Knockout Mice. EP1- and EP3-deficient homozygous mice (EP1−/− and EP3−/−) and wild-type mice received AOM (Sigma Chemical Co., St. Louis, MO) at a dose of 10 mg/kg body weight i.p. once a week for 3 weeks. The numbers of knockout mice treated with AOM were 9 for EP1, and 10 for EP3, and those of

References

1. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

2. This work was supported in part by a grant from the Organization for Pharmaceutical Safety and Research (OPSR) of Japan, a grant-in-aid for Cancer Research and a grant-in-aid for the Second-Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health and Welfare of Japan, and a grant-in-aid for Scientific Research from the Ministry of Education, Science, Sports, and Culture of Japan.

3. To whom requests for reprints should be addressed, at Cancer Prevention Division, National Cancer Center Research Institute, 1-1, Tsukiji S-chome, Chuo-ku, Tokyo 104-0045, Japan.

4. The abbreviations used are: NSAID, nonsteroidal anti-inflammatory drug; COX, cyclooxygenase; PG, prostaglandin; TX, thromboxane; ACF, aberrant crypt focus; AOM, azoxymethane; Apc, adenomatous polyposis coli; AC, aberrant crypt.

Received 7/6/99; accepted 9/3/99.
wild-type mice in each experiment were 10 and 7, respectively. All mice were sacrificed at 5 weeks after the first dosing of AOM. After laparotomy, the entire colon was resected and filled with 10% neutral buffered formalin and then opened longitudinally from the anus to the cecum. Each colon was then fixed flat between sheets of filter paper in 10% neutral buffered formalin, stained with 0.2% methylene blue in saline, and scored under a light microscope for the number of ACFs per colon and mean number of ACFs per focus, according to the procedure of Bird (19).  

A Selective EP<sub>1</sub> Antagonist, ONO-8711. A selective EP<sub>1</sub> antagonist, ONO-8711 \[6-\{(25,35)-3\-(4\text{-chloro-2-methylphenylsulfonylaminomethyl})\text{-bicyclo}[2.2.2]\text{-octan-2-yl}\}\text{-5-hexenoic acid}\] was chemically synthesized at Ono Pharmaceutical Co., Ltd. The structure of ONO-8711 is shown in Fig. 1. The K<sub>i</sub> values of this compound in Chinese Hamster Ovary cell lines, stably expressing each type of the prostanoid receptor (20), were 1.7 and 0.6 nM for mouse and human EP<sub>1</sub> receptors, respectively, and 67 nM for mouse EP<sub>3</sub> receptor and 76 nM for human TP receptor. Its 3<sup>m</sup>ppm ONO-8711 starting the day before the first treatment of AOM until the day of sacrifice at week 5 (post-AOM treatment). ACF in the colon of mice were detected in the colons of all mice treated with AOM but not in the colons of animals treated with vehicle (saline). The ACFs were located mostly in the distal colon, with fewer present in the middle colon and rectum. The data on ACFs for EP<sub>1</sub><sup>−/−</sup> mice and the wild-type mice are shown in Table 1. The number of ACFs per colon in EP<sub>1</sub><sup>−/−</sup> mice was reduced significantly, by ~40%, relative to that for wild-type animals. The mean number of ACs per focus in EP<sub>1</sub><sup>−/−</sup> mice did not differ from that in the wild-type mice. In contrast, there were no differences in the number of ACFs per colon and the mean number of ACs per focus between EP<sub>1</sub><sup>−/−</sup> mice and their wild-type counterparts (data not shown). The mean body weights of the AOM-treated EP<sub>1</sub><sup>−/−</sup> and EP<sub>3</sub><sup>−/−</sup> mice remained virtually identical to those of the AOM-treated wild-type animals 5 weeks after the first AOM injection. No abnormal signs were observed in the treated animals during the course of the experiment, and no difference in organ (liver, kidneys, or spleen) weights was apparent among the groups.  

Effect of ONO-8711 on AOM-induced ACF Development in C57BL/6J Mice and Intestinal Polyps in Min Mice. C57BL/6J male mice, 6 weeks of age, received i.p. injections of AOM or the vehicle (saline), as described above for the experiments for prostanoid receptor-knockout mice. The mice in the EP<sub>1</sub> antagonist-treated group were fed diets containing 250, 500, and 1000 ppm ONO-8711 starting the day before the first treatment of AOM until the end of the experiment at week 5. In addition, diets containing the antagonist were given to mice from 2 days after the last treatment of AOM to the day of sacrifice at week 5 (post-AOM treatment). ACF in the colon of mice were assessed as described above.

Min mice were fed a diet containing 500 ppm ONO-8711 or the basal diet from 6 weeks of age throughout the experiment for 7 weeks. All animals were sacrificed at 13 weeks of age. After laparotomy, the entire intestinal tract was resected, filled with 10% neutral buffered formalin, and divided into four sections: the colon and three segments of small intestine. The small intestine was divided into the duodenum (~4 cm in length; proximal) and the proximal (middle) and distal halves of the remainder (distal). These segments were opened longitudinally and fixed flat between sheets of filter paper in 10% neutral buffered formalin. The numbers and sizes of polyps as well as their distribution in the intestine were determined with a stereoscopic microscope.  

Table 1 Effect of EP<sub>1</sub> receptor deficiency on AOM-induced ACF formation in the mouse colon

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Mice with ACFs</th>
<th>ACFs/colon&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Mean of ACs/focus&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wild type</td>
<td>10/10</td>
<td>11.8 ± 1.3</td>
<td>1.7 ± 0.1</td>
</tr>
<tr>
<td>EP&lt;sub&gt;1&lt;/sub&gt;&lt;sup&gt;−/−&lt;/sup&gt;</td>
<td>9/9</td>
<td>7.6 ± 1.1&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1.6 ± 0.1</td>
</tr>
</tbody>
</table>

<sup>a</sup> Data are means ± SE.  
<sup>b</sup> P < 0.05 versus wild type.

Results

ACF Development in EP<sub>1</sub>- and EP<sub>3</sub>-Knockout Mice. ACFs were detected in the colons of all mice treated with AOM but not in the colons of animals treated with vehicle (saline). The ACFs were located mostly in the distal colon, with fewer present in the middle colon and rectum. The data on ACFs for EP<sub>1</sub><sup>−/−</sup> mice and the wild-type mice are shown in Table 1. The number of ACFs per colon in EP<sub>1</sub><sup>−/−</sup> mice was reduced significantly, by ~40%, relative to that for wild-type animals. The mean number of ACs per focus in EP<sub>1</sub><sup>−/−</sup> mice did not differ from that in the wild-type mice. In contrast, there were no differences in the number of ACFs per colon and the mean number of ACs per focus between EP<sub>1</sub><sup>−/−</sup> mice and their wild-type counterparts (data not shown). The mean body weights of the AOM-treated EP<sub>1</sub><sup>−/−</sup> and EP<sub>3</sub><sup>−/−</sup> mice remained virtually identical to those of the AOM-treated wild-type animals 5 weeks after the first AOM injection. No abnormal signs were observed in the treated animals during the course of the experiment, and no difference in organ (liver, kidneys, or spleen) weights was apparent among the groups.  

Effect of an EP<sub>1</sub> Antagonist on AOM-induced ACF Development in C57BL/6J Mice. Administration of the diets containing 250, 500, and 1000 ppm of a selective EP<sub>1</sub> antagonist, ONO-8711, to AOM-treated mice throughout the 5-week experimental period reduced the number of ACFs per colon in a dose-dependent manner (Table 2). In contrast, the mean number of ACs per focus in AOM-treated mice was not affected by administration of ONO-8711. Administration of ONO-8711 after AOM treatment also reduced the number of ACs per colon to almost the same extent as that apparent in animals who received the antagonist throughout the experimental period (Table 2). No ACFs were detected in five vehicle-injected mice fed a basal diet or in three vehicle-injected mice fed with the diet containing 1000 ppm of ONO-8711 throughout the experiment. Administration of the diets containing 250, 500, or 1000 ppm of ONO-

Table 2 Inhibition of AOM-induced ACF development in the colon of C57BL/6J mice by ONO-8711

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Intake of ONO-8711 (mg/kg/day)</th>
<th>Mice with ACFs</th>
<th>ACFs/colon&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Mean of ACs/focus&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basal diet</td>
<td></td>
<td>10/10</td>
<td>16.3 ± 1.2</td>
<td>1.4 ± 0.1</td>
</tr>
<tr>
<td>Mice fed ONO-8711 during and post-AOM</td>
<td>250 ppm</td>
<td>37</td>
<td>12.7 ± 1.0 (22)&lt;sup&gt;c&lt;/sup&gt;</td>
<td>1.4 ± 0.1</td>
</tr>
<tr>
<td>ONO-8711 (250 ppm)</td>
<td>71</td>
<td>10/10</td>
<td>11.3 ± 1.4 (31)&lt;sup&gt;d&lt;/sup&gt;</td>
<td>1.3 ± 0.1</td>
</tr>
<tr>
<td>ONO-8711 (1000 ppm)</td>
<td>141</td>
<td>10/10</td>
<td>10.6 ± 1.2 (35)&lt;sup&gt;d&lt;/sup&gt;</td>
<td>1.3 ± 0.0</td>
</tr>
<tr>
<td>Mice fed ONO-8711 post-AOM</td>
<td>250 ppm</td>
<td>35</td>
<td>13.4 ± 1.7</td>
<td>1.4 ± 0.1</td>
</tr>
<tr>
<td>ONO-8711 (250 ppm)</td>
<td>72</td>
<td>10/10</td>
<td>12.5 ± 1.7</td>
<td>1.3 ± 0.1</td>
</tr>
<tr>
<td>ONO-8711 (1000 ppm)</td>
<td>137</td>
<td>10/10</td>
<td>11.3 ± 0.9 (31)&lt;sup&gt;d&lt;/sup&gt;</td>
<td>1.2 ± 0.0</td>
</tr>
</tbody>
</table>

<sup>a</sup> Data are means ± SE.  
<sup>b</sup> Numbers in parentheses indicate percentage of inhibition compared with the basal diet group.  
<sup>c,d</sup> Versus basal diet: <sup>c</sup>P < 0.05; <sup>d</sup>P < 0.01.
8711 did not affect body or organ weight in either the AOM- or vehicle-injected groups. Thus, our pharmacological approach confirmed a role for the EP1 receptor in ACF development.

**Effect of an EP1 Antagonist on Intestinal Polyp Development in Min Mice.** Most polyps were located in the small intestine, with only a few apparent in the colons of the basal diet and ONO-8711 groups. Administration of ONO-8711 at a dose of 500 ppm in the diet for 7 weeks reduced the total number of polyps to 56% of the value for the basal diet group; the number of polyps in the middle and distal parts of small intestine were reduced to 61 and 54%, respectively, of the basal diet values (Table 3). Furthermore, ONO-8711 reduced the number of polyps in each size group (Fig. 2). Histological analysis revealed no differences in polyps between mice fed the basal diet and those exposed to ONO-8711. Administration of ONO-8711 did not affect body weight, food intake, or behavior of Min mice. 

**Discussion**

In the present study, examination of the effects of EP1 and EP3 receptors on AOM-induced ACF formation in mice provided evidence of an involvement of the PGE receptor subtype EP1, but not EP3, in colon carcinogenesis. The involvement of the EP1 receptor in colon carcinogenesis was confirmed using a novel EP1 antagonist, ONO-8711, in terms of ACF development. This antagonist was also effective in decreasing ACF formation, even when administered after AOM treatment. This indicates that the reduction of ACF formation by the antagonist was mediated not at the level of AOM metabolism but rather through postinitiation processes. Moreover, ONO-8711 clearly suppressed intestinal polyp formation in Min mice.

It has been reported that the number of AOM-induced ACFs per colon is reduced by 34–53%, relative to control values, by administration of traditional NSAIDs (sulindac and piroxicam) and COX-2-selective inhibitors (nimesulide and celecoxib) in rodents (21–23). The observed suppression potential is comparable to that of the EP1 antagonist, ONO-8711, shown in the present study. Inhibition rates for intestinal polyp formation in Min mice or Apc^(-/-) knockout mice with a traditional NSAID (sulindac) and the COX-2-selective inhibitors (nimesulide and MF-tricyclic) are reported to be 48–70% (9, 24, 25), again almost similar to that for ONO-8711. From the above observations, it is suggested that the EP1 receptor plays some role in colon carcinogenesis. Regarding prostaglandin receptors, eight lines of knockout mice have been developed. Among these, EP1- and EP3-knockout mice were used in the present study. In addition to the EP2- and EP4-knockout mice mentioned above, we were not able to study FP-knockout mice because of their limited availability as a result of delivery problems (12). Experiments with IP-, TP-, and DP-knockout mice will be carried out soon, but for the present, the question of whether EP2, EP3, FP, IP, TP, and DP receptors contribute to colon carcinogenesis remains open.

Inhibition of COX-1 by traditional NSAIDs such as indomethacin, sulindac, and piroxicam is accompanied by gastrointestinal side effects that limit the long-term application of these drugs as chemopreventive agents. Such adverse effects may be avoided by drugs that selectively target COX-2. Several types of prostanooids are produced as a result of COX activity in a variety of cells in response to various physiological or pathological stimuli (26). In light of the present results, selective EP1-receptor antagonists may prove particularly beneficial as chemopreventive agents for colon cancer with toxicities even lower than those of COX-2-selective inhibitors.

In conclusion, the data obtained in the present study strongly suggest that PGE2 mediates carcinogenic changes by acting at the EP1 receptor in the colon. To confirm this involvement of EP1, long-term colon carcinogenesis experiments with EP1-knockout mice and the EP1 antagonist are being conducted in our laboratory. Moreover, to extend our understanding, cross-breding of EP1 gene knockout and Apc gene knockout mice, and the expression of EP1 receptor in the colon need to be examined.

**Table 3 Inhibition of intestinal polyp development by ONO-8711 in Min Mice**

<table>
<thead>
<tr>
<th>Polyp location</th>
<th>No. of polyps per mouse&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basal diet</td>
<td>ONO-8711</td>
</tr>
<tr>
<td>Proximal small intestine</td>
<td>2.3 ± 0.9</td>
</tr>
<tr>
<td>Middle small intestine</td>
<td>3.2 ± 1.7</td>
</tr>
<tr>
<td>Distal small intestine</td>
<td>42.9 ± 6.2</td>
</tr>
<tr>
<td>Colon</td>
<td>0.9 ± 0.2</td>
</tr>
<tr>
<td>Total</td>
<td>59.3 ± 7.3</td>
</tr>
</tbody>
</table>

<sup>a</sup> Mice were fed the basal diet or a diet containing 500 ppm of ONO-8711 for 7 weeks. <sup>b</sup> Data are means ± SE. <sup>c</sup> Versus basal diet group; <sup>d</sup> p < 0.05; <sup>e</sup> p < 0.01.

**References**


Role of the Prostaglandin E Receptor Subtype EP₁ in Colon Carcinogenesis

Kouji Watanabe, Toshihiko Kawamori, Seiichi Nakatsugi, et al.


Updated version  Access the most recent version of this article at:  http://cancerres.aacrjournals.org/content/59/20/5093

Cited articles  This article cites 26 articles, 10 of which you can access for free at:  http://cancerres.aacrjournals.org/content/59/20/5093.full.html#ref-list-1

Citing articles  This article has been cited by 80 HighWire-hosted articles. Access the articles at:  /content/59/20/5093.full.html#related-urls

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.